EMA welcomes political settlement on Vital Medicines Act

In current years, EU Member States have confronted severe medication shortages and international challenges such because the COVID-19 pandemic and geopolitical tensions have uncovered vulnerabilities within the pharmaceutical provide chain. Shortages of medicines can put sufferers’ lives in danger and place a major burden on healthcare techniques. They could come up from causes together with manufacturing points, provide chain vulnerabilities or international competitors for assets.

By combining regulatory instruments with focused industrial coverage measures, the CMA strengthens preparedness and helps a extra resilient provide of medicines for sufferers. It builds on the regulatory instruments launched via EMA’s prolonged mandate and enhances the measures within the revised EU pharmaceutical laws, to strengthen manufacturing capability and provide resilience for crucial medicines. It additionally goals to enhance entry to different medicines of widespread curiosity which will not be obtainable in sure EU markets, reminiscent of medicines for uncommon illnesses.

To assist the CMA, EMA is already advancing key areas of labor. For instance, the Act foresees a task for EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) in finishing up provide chain vulnerability assessments to tell measures geared toward addressing structural vulnerabilities within the provide chain of crucial medicines. This work will inform choices on applicable coverage measures to assist the strengthening of provide chains of crucial medicines, below the brand new pharmaceutical laws (e.g. MSSG suggestions) and the CMA (e.g. strategic tasks and public procurement procedures).

In preparation for the implementation of the CMA and the brand new pharmaceutical laws, the MSSG is evaluating vulnerabilities within the provide chains of a primary set of medicines included within the Union listing of crucial medicines. This listing incorporates over 200 energetic substances of medicines for human use which might be thought of crucial for healthcare techniques throughout the EU.

The CMA additionally recognises and strengthens the function of the Quality Innovation Expert Group (QIG) which EMA established in 2022 to assist builders of revolutionary applied sciences.

EMA can be increasing the functionalities of the European Shortages Monitoring Platform (ESMP), a digital software designed to allow sooner, extra constant and extra data-driven exchanges on potential medicines shortages between trade and regulators.

In addition, the Agency welcomes the CMA proposals on state help and joint procurement, which, whereas exterior EMA’s direct remit, could contribute to enhancing entry to and availability of crucial medicines throughout the EU.

EMA will work carefully with the European Commission and EU Member States, in assist of the implementation of the CMA.

The CMA was proposed in 2025 by the European Commission within the context of the European Health Union, which seeks to make sure that all EU residents have entry to vital medicines. It enhances regulatory measures already proposed to handle medication shortages and strengthen provide within the EU, notably within the new EU pharmaceutical laws.